ACKR1在尿路上皮膀胱癌组织中的表达及其与预后的相关性  

Expression of ACKR1 in urothelial bladder cancer and its correlation with prognosis

作　　者：李如鹏 罗蓉 赵建 高宏飞[1] LI Rupeng;LUO Rong;ZHAO Jian;GAO Hongfei(Department of Urology,the First Hospital of Shanxi Medical University,Shanxi Taiyuan 030001,China;Pathology Department,Wan Bailin Center Hospital,Shanxi Taiyuan 030024,China)

机构地区：[1]山西医科大学第一医院泌尿外科,山西太原030001 [2]太原市万柏林中心医院病理科,山西太原030024

出　　处：《现代肿瘤医学》2024年第20期3942-3947,共6页Journal of Modern Oncology

基　　金：2023年度太原市“六个一批”科研项目(重点项目)(编号:Z2023005)。

摘　　要：目的:探讨非典型趋化因子1(ACKR1)在尿路上皮膀胱癌(UBC)组织中的表达情况,并探讨其与预后的相关性。方法:收集428例UBC样本转录组基因表达数据进行差异基因分析并用ESTIMATE法进行肿瘤免疫微环境分析。随后,回顾性分析2019年1月至2021年12月我院泌尿外科收治的81例膀胱癌患者的临床资料,根据患者预后分为复发组(n=42)和未复发组(n=39),比较两组各临床特征的差异。采用免疫组织化学法检测组织中ACKR1表达情况,比较膀胱壁各层瘤内组织与瘤周组织ACKR1表达差异,并分析其与UBC患者临床病理特征的关系;采用乘积极限法(Kaplan-Meier)分析UBC患者预后状况,并采用Log-Rank检验进行显著性比较;采用Cox模型分析UBC患者不良预后的影响因素。结果:428例样本数据的差异表达基因分析发现ACKR1在肿瘤组织内表达下降并且与较低的免疫评分相关。81例UBC患者样本的IHC结果结合临床资料发现在未复发组中固有层瘤周组织的ACKR1表达量要高于复发组。另外,存在肿瘤细胞血管浸润者较不存在者的ACKR1表达量更低,且差异具有统计学意义。与ACKR1低表达组相比,ACKR1高表达组患者具有更长无复发生存期且P<0.001。单因素Cox回归分析表明分化级别、浸润深度、肿瘤大小、脉管浸润及ACKR1表达与患者复发相关;多因素Cox回归分析表明ACKR1表达为膀胱癌复发的独立影响因素(P<0.05),即与ACKR1低表达的患者相比,ACKR1高表达的患者复发风险较低(OR=0.032,95%CI:0.0041~0.24,P<0.05)。结论:固有层瘤周组织内毛细血管内皮细胞表面的ACKR1低表达的患者可能倾向于较短的无复发生存期。Objective:To investigate the expression of atypical chemokine 1(ACKR1)in urothelial bladder cancer(UBC)and its prognostic relevance.Methods:Transcriptome gene expression data from 428 UBC samples were collected for differential gene analysis and analysis of the tumor immune microenvironment using the ESTIMATE method.The clinical data of 81 bladder cancer patients admitted to the department of urology at our hospital from January 2019 to December 2021 were retrospectively analyzed.The patients were divided into a recurrence group(n=42)and a non-recurrence group(n=39)based on their prognosis.The study compared the clinical features between the two groups to identify any differences.Immunohistochemistry was used to detect ACKR1 expression in tissues and compare the differences in expression between intratumoral and peritumoral tissues in each layer of the bladder wall.The relationship between ACKR1 expression and clinicopathological characteristics of UBC patients was analyzed.The prognostic status of UBC patients was analyzed using the product-limit method(Kaplan Meier),and the significance of the comparisons was determined using the Log-Rank test.The Cox model was used to analyze the factors influencing poor prognosis in UBC patients.Results:Analysis of gene expression data from 428 samples showed that the expression of ACKR1 was reduced in tumor tissue and correlated with lower immune scores.The immunohistochemistry results of 81 patients with UBC combined with clinical data showed that the expression of ACKR1 in the peritumoral tissue of the lamina propria was higher in the non-recurrent group than in the recurrent group.Furthermore,individuals with tumor cells infiltrating the vasculature exhibited lower levels of ACKR1 expression compared to those without,and this difference was statistically significant.The group of patients with high expression of ACKR1 had a longer recurrence-free survival compared to the group with low expression of ACKR1(P<0.001).The results of the univariate Cox regression analysis indic

关 键 词：膀胱癌 ACKR1 趋化因子 血管浸润 肿瘤免疫微环境 

分 类 号：R737.14[医药卫生—肿瘤]